AI Article Synopsis
- Temozolomide is a new chemotherapy drug that can lead to a decrease in CD4+ T-lymphocytes, which are important for the immune system.
- Patients with weakened immune systems, like those receiving this treatment, are more susceptible to infections, specifically with Salmonella bacteria.
- The text presents the first documented case of a patient who developed a serious Salmonella infection after being treated with temozolomide.
Article Abstract
Temozolomide is a relatively new chemotherapeutic agent frequently associated with selective CD4+ T-lymphocytopenia. Patients with cell-mediated immune defects are at higher risk for acquiring infections with Salmonella species. We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jinf.2008.06.021 | DOI Listing |
Publication Analysis
Top Keywords
disseminated salmonellosis
8
salmonellosis patient
8
patient treated
8
treated temozolomide
8
temozolomide temozolomide
4
temozolomide chemotherapeutic
4
chemotherapeutic agent
4
agent frequently
4
frequently associated
4
associated selective
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!